Patent US3292018A successfully refreshed from Google Patents.
US4957902A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptide inhibitors of wound contraction
Assignee: The University of Texas System
•
Filing: 1988-12-20
•
Granted: 1990-09-18
•
Expires: 2008-12-20
Abstract
Abstract The present invention involves the inhibition of wound contraction by polypeptides having an amino acid sequence which is similar or identical to certain amino acid sequences of type (I) collagen. A variety of peptides are disclosed which are clinically useful as inhibitors of wound contraction.
Inventors
- 👤 Frederick Grinnell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 09:22
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; C07K5/00; C07K5/04; C07K5/08; C07K5/0815; C07K5/0817; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
148 words
A method for inhibiting wound contraction in an individual having a wound, the method comprising the steps of: providing a pharmaceutically acceptable composition including, as the active principle, a polypeptide compound having the sequence: X--NH--Arg--Gly--Glu--CO--Y 1 2 3 wherein X is a pharmaceutically acceptable N terminal derivative, or is selected from the group consisting of Z--NH--Val, Z--NH--Gly--Val, Z--NH--Ala, Z--NH--Gly--Ala, Z--NH--Glu, Z--NH--Gly--Glu, Z--NH--Leu, Z--NH--Gly--Leu, Z--NH--Asp, Z--NH--Gly--Asp, Z--NH--Ser, Z--NH--Gly--Ser, Z--NH--Pro, Z--NH--Gly--Pro, Z--NH--Gln, Z--NH--Gly--Gln, and Z--NH--Gly, where Z is a pharmaceutically acceptable N-terminal derivative thereof, wherein Y is a pharmaceutically acceptable C--terminal derivative, or is selected from the group consisting of --Hyp--CO--R, --Hyp--Gly--CO--R, --Gln--CO--R, --Gln--Gly--CO--R, --Arg--CO--R, --Arg--Gly--CO--R, --Thr--CO--R, --Thr--Gly--CO--R, --Ile--CO--R, --Ile--Gly--CO--R, --Ala--CO--R, --Ala--Gly--CO--R, --Val--CO--R, --Val--Gly--CO--R, --Ser--CO--R, and --Ser--Pro--CO--R, where R is a pharmaceutically acceptable C terminal derivative thereof; and administering said pharmaceutically acceptable composition to an individual so that a wound being treated is exposed to a therapeutically effective amount thereof.
Claim 2
Independent Claim
148 words
A method for inhibiting wound contraction in an individual having a wound, the method comprising the steps of: providing a pharmaceutically acceptable composition including, as the active principle, a polypeptide compound having the sequence: X--NH--Arg--Gly--Glu--CO--Y 1 2 3 wherein X is a pharmaceutically acceptable N terminal derivative, or is selected from the group consisting of Z--NH--Val, Z--NH--Gly--Val, Z--NH--Ala, Z--NH--Gly--Ala, Z--NH--Glu, Z--NH--Gly--Glu, Z--NH--Leu, Z--NH--Gly--Leu, Z--NH--Asp, Z--NH--Gly--Asp, Z--NH--Ser, Z--NH--Gly--Ser, Z--NH--Pro, Z--NH--Gly--Pro, Z--NH--Gln, Z--NH--Gly--Gln, and Z--NH--Gly, where Z is a pharmaceutically acceptable N-terminal derivative thereof, wherein Y is a pharmaceutically acceptable C--terminal derivative, or is selected from the group consisting of --Hyp--CO--R, --Hyp--Gly--CO--R, --Gln--CO--R, --Gln--Gly--CO--R, --Arg--CO--R, --Arg--Gly--CO--R, --Thr--CO--R, --Thr--Gly--CO--R, --Ile--CO--R, --Ile--Gly--CO--R, --Ala--CO--R, --Ala--Gly--CO--R, --Val--CO--R, --Val--Gly--CO--R, --Ser--CO--R, and --Ser--Pro--CO--R, where R is a pharmaceutically acceptable C terminal derivative thereof; and administering said pharmaceutically acceptable composition to an individual so that a wound being treated is exposed to a therapeutically effective amount thereof.
Claim 3
Dependent Claim
12 words
The method of claim 1 wherein the polypeptide has the formula: Arg--Gly--Glu.
Claim 4
Dependent Claim
12 words
The method of claim 1 wherein the polypeptide has the formula: Gly--Arg--Gly--Glu--Ser--Pro.
Claim 5
Dependent Claim
16 words
The method of claim 1 wherein the polypeptide is incorporated into a longer amino acid sequence.
Claim 6
Dependent Claim
21 words
The method of claim 1 wherein the providing step involves biogenic synthesis, chemical synthesis or excision from a polypeptide or protein.
Claim 7
Independent Claim
122 words
A method for inhibiting contraction of a wound, the method comprising: applying to the wound a pharmaceutically acceptable solution comprising a therapeutically effective level of a polypeptide compound having the sequence: X--NH--Arg--Gly--Glu--CO--Y 12 3 wherein X is a first pharmaceutically acceptable N-terminal derivative, or is selected from the group consisting of Z--NH--Val, Z--NH--Gly--Val, Z--NH--Ala, Z--NH--GlyAla, Z--NH--Glu, Z--NH--Gly--Glu, Z--NH--Leu, Z--NH--Gly--Leu, Z--NHAsp, Z--NH--Gly--Asp, Z--NH--Ser, Z--NH--Gly--Ser, Z--NH--Pro, Z--NH--Gly--Pro, Z--NH--Gln, Z--NH--Gly--Gln, and Z--NH--Gly, where Z is a second pharmaceutically acceptable N-terminal derivative; wherein Y is a first pharmaceutically acceptable C-terminal derivative, or is selected from the group consisting of --Hyp--CO--R; --Hyp--Gly--CO--R, --Gln--CO--R, --Gln--Gly--CO--R, --Arg--CO--R, --Arg--Gly--CO--R, --Thr--CO--R, --Thr--Gly--CO--R, --Ile--CO--R, --Ile--Gly--CO--R, --Ala--CO--R, --Ala--Gly--CO--R, --Val--CO--R, --Val--Gly--CO--R, --Ser--CO--R, and --Ser--Pro--Co--R, where R is a second pharmaceutically acceptable C terminal derivative.
Claim 8
Independent Claim
122 words
A method for inhibiting contraction of a wound, the method comprising: applying to the wound a pharmaceutically acceptable solution comprising a therapeutically effective level of a polypeptide compound having the sequence: X--NH--Arg--Gly--Glu--CO--Y 12 3 wherein X is a first pharmaceutically acceptable N-terminal derivative, or is selected from the group consisting of Z--NH--Val, Z--NH--Gly--Val, Z--NH--Ala, Z--NH--GlyAla, Z--NH--Glu, Z--NH--Gly--Glu, Z--NH--Leu, Z--NH--Gly--Leu, Z--NHAsp, Z--NH--Gly--Asp, Z--NH--Ser, Z--NH--Gly--Ser, Z--NH--Pro, Z--NH--Gly--Pro, Z--NH--Gln, Z--NH--Gly--Gln, and Z--NH--Gly, where Z is a second pharmaceutically acceptable N-terminal derivative; wherein Y is a first pharmaceutically acceptable C-terminal derivative, or is selected from the group consisting of --Hyp--CO--R; --Hyp--Gly--CO--R, --Gln--CO--R, --Gln--Gly--CO--R, --Arg--CO--R, --Arg--Gly--CO--R, --Thr--CO--R, --Thr--Gly--CO--R, --Ile--CO--R, --Ile--Gly--CO--R, --Ala--CO--R, --Ala--Gly--CO--R, --Val--CO--R, --Val--Gly--CO--R, --Ser--CO--R, and --Ser--Pro--Co--R, where R is a second pharmaceutically acceptable C terminal derivative.
Claim 9
Dependent Claim
19 words
The method of claim 6 wherein the therapeutically effective level is between about 0.1 mg/ml and about 1 mg/ml.
Claim 10
Dependent Claim
12 words
The method of claim 6 wherein the polypeptide has the formula: Arg--Gly--Glu.
Claim 11
Dependent Claim
12 words
The method of claim 6 wherein the polypeptide has the formula: Gly--Arg--Gly--Glu--Ser--Pro.
Claim 12
Dependent Claim
16 words
The method of claim 6 wherein the polypeptide is incorporated into a longer amino acid sequence.
Claim 13
Dependent Claim
25 words
The method of claim 6 wherein the polypeptide is produced by a method involving biogenic synthesis, chemical synthesis or excision from a polypeptide or protein.
Claim 14
Dependent Claim
12 words
The method of claim 6 wherein X is hydrogen, alkyl, or acetyl.
Claim 15
Dependent Claim
16 words
The method of claim 6 wherein Y is OH, an ester, an amide or a salt.
Claim 16
Dependent Claim
12 words
The method of claim 6 wherein Z is hydrogen, alkyl, or acetyl.
Claim 17
Dependent Claim
16 words
The method of claim 6 wherein R is OH, an ester, an amide or a salt.
Claim 18
Dependent Claim
15 words
The method of claim 1 or 6 wherein the administration is topical, subcutaneous or intramuscular.
References Cited (Backward Citations)
US4578079A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-17 | 1994-03-19 | 1994-09-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-17 | 1998-03-19 | 1998-09-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-17 | 2002-03-19 | 2002-09-18 | $7700.00 | Window Closed / Lapsed |